How does aurobindo verify clonazepam dosage accuracy?

Aurobindo's Quality Control for Clonazepam

Aurobindo Pharma verifies clonazepam dosage accuracy through standard pharmaceutical manufacturing practices compliant with FDA Good Manufacturing Practices (GMP). This includes in-process controls during tablet compression and coating, where active ingredient content is tested at multiple stages to ensure each dose (typically 0.5 mg, 1 mg, or 2 mg) falls within 90-110% of the labeled amount, per USP monograph standards for clonazepam tablets.[1]

Testing Methods Used

- Content Uniformity Testing: Samples from each batch undergo HPLC (high-performance liquid chromatography) to measure clonazepam concentration in individual tablets, confirming low variability (relative standard deviation <6%). Dissolution testing ensures at least 80% release in 30 minutes in simulated gastric fluid.[2]
- Batch Release Testing: Finished batches are assayed for potency, impurities (e.g., benzodiazepinone <0.5%), and weight variation before FDA approval for distribution.[1]

Regulatory Oversight and Recalls

The FDA inspects Aurobindo's facilities (e.g., India and US sites) for dosage verification protocols. Aurobindo has faced recalls for clonazepam, such as in 2020 for subpotent tablets (Lots 18G401 and 18G402, failing potency specs), resolved via enhanced testing.[3] No active clonazepam patents limit generics like Aurobindo's; generics compete on ANDA approval proving bioequivalence.[4]

Sources
[1]: FDA GMP Guidelines for Finished Pharmaceuticals
[2]: USP Monograph: Clonazepam Tablets
[3]: FDA Recall Notice: Aurobindo Clonazepam
[4]: DrugPatentWatch: Clonazepam Patents